Deutsch names Dowshen to head Zelnorm and Diovan business

Share this article:
Deutsch named Matt Dowshen to head the firm's business on Novartis' Zelnorm and Diovan. Dowshen, who joined from JWT New York, where he was senior partner/director-in-charge and co-leader of the DeBeers account, becomes SVP/group account director at Deutsch New York. In addition to the Novartis business, he will head the firm's IKEA account, reporting to Deutsch New York president Val DiFebo.
Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.